Review Article

CXCR4 in Cancer and Its Regulation by PPARγ

Cynthia Lee Richard1,2 and Jonathan Blay1

1 Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5
2 Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1

Correspondence should be addressed to Jonathan Blay, jonathan.blay@dal.ca

Received 4 April 2008; Revised 25 June 2008; Accepted 10 July 2008

Recommended by Dipak Panigrahy

Chemokines are peptide mediators involved in normal development, hematopoietic and immune regulation, wound healing, and inflammation. Among the chemokines is CXCL12, which binds principally to its receptor CXCR4 and regulates leukocyte precursor homing to bone marrow and other sites. This role of CXCL12/CXCR4 is “commandeered” by cancer cells to facilitate the spread of CXCR4-bearing tumor cells to tissues with high CXCL12 concentrations. High CXCR4 expression by cancer cells predisposes to aggressive spread and metastasis and ultimately to poor patient outcomes. As well as being useful as a marker for disease progression, CXCR4 is a potential target for anticancer therapies. It is possible to interfere directly with the CXCL12:CXCR4 axis using peptide or small-molecular-weight antagonists. A further opportunity is offered by promoting strategies that downregulate CXCR4 pathways: CXCR4 expression in the tumor microenvironment is modulated by factors such as hypoxia, nucleosides, and eicosanoids. Another promising approach is through targeting PPAR to suppress CXCR4 expression. Endogenous PPARγ such as 15-deoxy-Δ12,14-PGJ2 and synthetic agonists such as the thiazolidinediones both cause downregulation of CXCR4 mRNA and receptor. Adjuvant therapy using PPARγ agonists may, by stimulating PPARγ-dependent downregulation of CXCR4 on cancer cells, slow the rate of metastasis and impact beneficially on disease progression.

Copyright © 2008 C. L. Richard and J. Blay. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

The regulation of the distribution of motile cells in both normal and disease situations depends upon a variety of peptide and nonpeptide mediators, which stimulate cell movement by both directed (chemotaxis) and nondirected (chemokinesis) mechanisms. Amongst these mediators are the chemokines, a class of peptide mediators that play critical roles in normal development, regulation of the hematopoietic and immune systems in the adult, and in repair processes such as wound healing and inflammation. Among the different chemokines is the stromal cell-derived factor-1 (SDF-1), which is now known as CXCL12. CXCL12 binds principally to the receptor CXCR4, although it also acts through the more-recently-described receptor CXCR7 [1]. This review describes the roles of CXCL12 and CXCR4 in normal tissue functions and in cancer, and suggests that the regulation of CXCR4 expression by PPARγ may emerge to be a unique avenue by which a key receptor involved in cancer cell metastasis can be suppressed in a way that will assist with disease therapy.

2. CHEMOKINES AND THEIR RECEPTORS IN CELL REGULATION

Chemokines are low-molecular-weight peptide ligands involved in the trafficking of leukocytes and other motile cells [2, 3]. There are four major groups of chemokines, the CXC, CC, C and CX3C chemokines, categorized as such on the basis of their number and spacing of conserved cysteine residues [2, 4]. The nomenclature of chemokines (e.g., “CXCL12”) is made up of their subclass (CXC, CC, etc.) followed by “L” for ligand, and a specific number [2, 3].

The receptors for chemokines are cell-surface, seven-transmembrane G protein-coupled receptors [2]. The naming of these receptors (e.g., “CXCR4”) is based on the subclass of chemokine that the receptor recognizes, followed by “R” for receptor and a number (which need not correspond
to the number assigned to its cognate ligand(s)). There are 19 well-recognized chemokine receptors (e.g., CXCR1-6, CCR1-10, CX3CR1, and XCR1) [1, 5]. Many chemokine receptors have more than one known ligand, and many chemokines can activate more than one receptor. Thus, there is much promiscuity in chemokine/receptor signaling.

Chemokines bind within the extracellular domain of the chemokine receptor, which comprises the N-terminus and three extracellular loops [3]. The intracellular domain, which consists of three loops and the C-terminus, associates with G proteins that, upon activation, lead to inhibition of adenyl cyclase activity [3]. Typical cellular consequences of chemokine binding include changes in gene expression, cell polarization, and chemotaxis (directed cell migration) [4].

Chemokines play a major role in regulating the migration of cells of the immune system, leading to the modulation of immune responses. Their exact role depends on the expression pattern of receptors on specific leukocyte subsets [2] but encompasses the regulation of lymphocyte trafficking, lymphoid tissue development, Th1/Th2 modulation, and the effecting of inflammatory reactions. Chemokine receptors are also found on other cell types, and play a part in stem cell recruitment and angiogenesis, in development and wound healing [4]. When such pathways are subverted in neoplastic cells, chemokines take over prominent roles in the metastatic process, both in terms of the dissemination of cells from primary tumors and in growth of the cancer at metastatic sites. As we will see, this is the case for CXCR4.

3. THE CHEMOKINE RECEPTOR CXCR4 AND ITS LIGAND CXCL12 (SDF-1)

The receptor now known as CXCR4 was cloned in 1994, and was originally given the name leukocyte-expressed seven-transmembrane domain receptor (LESTR) due to its abundant expression in several leukocyte populations [6]. It was independently cloned by others and named “fusin” because of its ability to act as a coreceptor for HIV fusion and entry [7]. It further has the designation “CD184” as part of the cluster of differentiation antigens found on activated leukocytes. LESTR/fusin/CD184 was originally considered to be an orphan receptor. However, the chemokine CXCL12, originally termed stromal cell-derived factor 1 (SDF-1), was shown by two independent research groups to be a ligand for LESTR/fusin/CD184, and the name CXCR4 was proposed [8, 9]. The CXCR4 gene is constitutively expressed, and CXCR4 protein has been detected on many leukocytes, including lymphocytes, monocytes, NK cells, and dendritic cells; as well as on vascular smooth muscle cells, endothelial cells, cells lining the gastrointestinal tract, microglia, neurons, and astrocytes [10–13]. Until recently, CXCR4 was considered to be the only receptor for CXCL12, but the previous orphan receptor RDC1 is now recognized as an additional CXCL12 receptor, for which the name CXCR7 has been given [1]. CXCL12 itself is widely expressed at different levels in many tissues [14].

4. CXCL12 AND CXCR4 IN NORMAL TISSUE FUNCTION

The interplay between CXCL12 and CXCR4 is critical to normal development. Indeed (and unlike mice deficient in other chemokine/receptors) mice lacking CXCL12 or CXCR4 die in utero or shortly after birth [2, 15–17]. CXCL12/CXCR4 signaling is required during the development of the hematopoietic, cardiac, vascular, and nervous systems. Absence of this axis in embryonic life leads to defects in bone marrow myeloid cell formation, cardiac dysfunction due to impaired ventricular septum formation, and developmental defects in the cerebellum and in the vasculature of the gastrointestinal tract [15–17].

In the normal adult, CXCL12 and CXCR4 are involved in the homing and retention of hematopoietic progenitor cells in the bone marrow. These progenitor cells express high levels of CXCR4, and are attracted to CXCL12 produced by stromal cells in specialized bone marrow niches [18]. Activating mutations of the CXCR4 gene lead to aberrant retention of myeloid cells within the bone marrow [19]. CXCL12 also acts as a chemoattractant for stem cells and some differentiated cells in the pathological contexts of inflammation and tissue regeneration/repair [20–24]. It is this function of controlling cell migration and homing that is subverted in cancer.

5. CXCL12 AND CXCR4 IN CANCER METASTASIS AND GROWTH

In many ways, the process of metastasis is similar to leukocyte and stem cell trafficking, processes which involve the CXCL12/CXCR4 axis [20]. Cancer cells that express CXCR4 exploit the same signaling pathway, leading to homing and retention in tissues that are rich in CXCL12.

The foundation for our appreciation of the role that CXCR4 and CXCL12 may play in cancer metastasis was set in 2001, when a landmark study by Albert Zlotnik’s group demonstrated the importance of the CXCL12/CXCR4 axis in site-specific metastasis of breast cancer [25]. In that study, it was found that CXCR4 expression was low or undetectable in normal epithelial cells, but consistently upregulated in breast cancer cell lines and primary breast cancer cells at both the mRNA and protein level. Human breast carcinoma cells that expressed high levels of CXCR4 underwent morphological changes and migrated directionally in response to CXCL12, indicating that the CXCR4 receptor was active. Crucially, the ligand CXCL12 was highly expressed in tissues taken from human organ sites to which breast cancer cells metastasize, including lymph nodes, lung, liver, and bone marrow, but expressed at low levels in tissues that represent rare sites of metastasis, including the kidney, skin, and muscle. The ability of MDA-MB-231 human breast cancer cells (a cell line that is metastatic in experimental models) to migrate towards protein extracts of lung and liver, or to produce lung and lymph node metastasis after tail-vein injection or orthotopic implantation, was inhibited by neutralizing anti-CXCR4 and/or anti-CXCL12 antibodies. These findings were the first to show the biological importance of this
chemokine/receptor pair in the evolution and spread of cancer.

Since that time, the CXCL12/CXCR4 axis has been shown to be important in the progression and spread of more than 25 different cancers. Our present knowledge is based on (i) studies in cellular and animal experimental models, (ii) surveys of human tissues at different stages of cancer progression, and (iii) population-based studies of morbidity and survival. A summary of present data is shown in Table 1.

CXCR4 has been shown to be expressed at high levels on cells of all of the major adult solid epithelial cancers (breast, colorectal, lung, ovary, prostate, etc.). The ability of the cells to colonize other tissues by gaining advantage from CXCR4-dependent mechanisms depends on the presence of CXCL12 in the tissue fluid. Various studies have shown significant CXCL12 concentrations in the fluid-filled cavities through which many cancers disseminate, and at tissue locations in which metastases characteristically develop. Biologically, significant CXCL12 levels have been found in peritoneal ascites from ovarian cancer patients [26], pleural effusions in lung cancer [27], lymph nodes, bone, and lungs as well as other tissues [25, 28, 29].

Detailed studies of the cellular interactions involved in the metastasis of prostate cancer cells to bone [29] have shown that the interaction of CXCL12 with CXCR4 plays a major role in successive steps in the metastatic process. Human osteoblasts express CXCL12 mRNA and protein, whereas prostate cancer cells express CXCR4 mRNA and receptor. Prostate cancer cells that have become disseminated into the circulation respond to the CXCL12-CXCR4 pathway by enhanced adherence to the bone marrow endothelium and migration across endothelial barriers and basement membranes, ultimately adhering to components of the bone marrow in response to a CXCL12 gradient [29]. CXCL12 from osteoblasts has also been shown to act on CXCR4 to induce release of IL-6 from human squamous cell carcinoma cells to promote osteoclastogenesis [30].

As well as promoting the migration of cancer cells and their invasion through physical barriers as well as adherence to target structures, CXCL12 can act upon CXCR4 on the cancer cells to promote cancer cell growth along with other mitogenic factors. This has been shown in cells from colorectal [31], prostate [32], and ovarian [33] cancers. Furthermore, CXCL12 can promote cancer cell growth indirectly by enhancing the vascular supply, since the CXCL12/CXCR4 axis may also promote tumor angiogenesis. Vascular endothelial growth factor (VEGF) and CXCL12 have been shown to increase angiogenesis synergetically in an in vivo Matrigel assay and to promote proliferation and migration of human umbilical vein endothelial cells (HUVECs) in vitro [34].

6. THE EFFECT OF CXCL12 ON CELLULAR PROCESSES

Activation of CXCR4 produces specific cellular changes that are consistent with a migratory and invasive cell phenotype. Exposure of cells to CXCL12 produces upregulation of matrix metalloproteinases (MMPs) such as MMP-2 and MMP-9 [25, 26, 29, 35–39]. In addition, CXCL12 enhances adhesion to components of the extracellular matrix such as fibronectin, laminin, and collagen types I/III [37, 40], or to other cell types (e.g., endothelial or bone marrow stromal cells) [29, 41, 42]. These changes are mediated in large part by integrin signaling [29, 43, 44]. Many signaling pathways are activated by CXCL12 downstream of CXCR4 in cancer cells. For example, CXCL12 has been shown to increase ERK1/2 phosphorylation [30, 31, 49, 07, 76, 78, 79], Akt phosphorylation [50, 77.88], and PI3K activation [45].

7. CXCR4 IN BREAST CANCER

CXCR4 is expressed at a low level in normal breast epithelium but becomes more strongly expressed in the early stages of carcinogenesis, showing both a more intense immunohistochemical staining pattern and an altered cellular localization in studies of human ductal carcinoma in situ (DCIS) [46, 47]. An extensive tissue microarray study of 1808 invasive breast carcinomas and 214 pre-invasive breast samples linked to clinical data has shown that the level of CXCR4 expression can be linked to tumor progressivity (tumor grade and lymph node status) and to other prognostic factors such as HER2 expression and hormone receptor (ER and PR) negativity, as well as to patient survival [46]. These observations in human tissues have led to the view that CXCR4 provides a selective advantage to newly formed neoplastic cells in the early primary breast tumor as well as being important to later invasion and metastasis [13, 46–48]. This is consistent with observations in mouse models of breast cancer in which interventions affecting CXCR4 reduced both growth of the primary tumor and metastasis [49].

Prominent CXCR4 expression is a feature of all major histological forms of invasive breast cancer, including ductal, lobular, mucinous [46], and the distinctive and highly aggressive inflammatory form of the disease [50]. Several independent studies have shown that the extent and pattern of CXCR4 expression is related to axillary lymph node involvement in different forms and stages of breast cancer [28, 51–53]. CXCR4 positivity has also been noted as a key feature of breast carcinoma metastasis to bone [54] and brain [55]. The power of CXCR4 as a marker for lymph node metastasis can be greatly increased by concurrently examining the expression of additional markers such as VEGF, MMP-9, and CCR7 [38, 56]. Furthermore, CXCR4 is also one of a subset of markers (the others are uPAR, S100A4, and vimentin) that define highly aggressive and invasive breast carcinoma cells that are associated with malignant pleural or peritoneal effusions in breast cancer patients [57]. CXCR4 expression is therefore a general marker for the spread of breast cancer to its secondary sites, and for aggressive stages of the disease.

There is evidence not only for the use of CXCR4 as a general marker for the progression and metastasis of breast cancer, but also for the identification of individual tumor cells as they are homing from the primary tumor to secondary sites as patients develop metastatic disease. Individual CXCR4-expressing tumor cells have been found...
| Cancer                      | Comments                                                                                                                                  | References |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Acute lymphoblastic leukemia | Levels of CXCR4 are elevated on lymphoblasts. Elevated levels of CXCR4 are associated with increased infiltration in liver and spleen     | [58]       |
| Acute myelogenous leukemia  | High CXCR4 expression is associated with relapse and reduced survival                                                                      | [59]       |
| Brain cancer                | CXCR4 expression is demonstrated in tissues and cell lines derived from glioblastoma, medulloblastoma, and astrocytoma. Cell lines respond to CXCL12 with increased proliferation, survival and migration. Gliomas expressing CXCR4 are associated with increased tumor size and reduced survival | [41, 60–64]|
| Breast cancer               | High CXCR4 expression is noted in breast cancer tissues compared to normal tissues and cell lines with invasive characteristics. CXCR4 expression is associated with more extensive lymph node metastasis and with liver metastasis, although CXCR4 expression in lymph node metastases may be lower than primary cancers. CXCR4 co-expression with HER2/neu is an indicator of more extensive lymph node involvement | [25, 28, 65–67]|
| Cervical cancer             | CXCR4 expression is associated with increased tumor size, stromal invasion, lymph node metastasis, and reduced survival                   | [68]       |
| Chronic lymphocytic leukemia | Malignant B cells express 3- to 4-fold higher cell-surface CXCR4 levels than normal B cells. High CXCR4 expression on B cells is associated with reduced survival in patients with familial chronic lymphocytic leukemia | [69, 70]   |
| Colorectal cancer           | CXCR4 is over-expressed in colorectal carcinoma tissues compared to normal tissues, and on certain established cell lines. In patients with liver metastasis, higher CXCR4 expression is found on liver metastases compared to the primary tumor. In patients with stage I/II disease, high CXCR4 mRNA expression in tumor samples is associated with increased disease recurrence. In patients with stage IV disease, patients with high CXCR4 have decreased overall survival. High CXCR4 expression is associated with increased lymph node involvement and distant metastasis, as well as reduced 3-year survival | [40, 71–75]|
| Endometrial cancer          | Endometrial adenocarcinoma tissues and human cell lines express CXCR4 protein. CXCL12 induces proliferation of endometrial carcinoma cells | [76]       |
| Esophageal cancer           | CXCR4 expression is associated with reduced survival and increased lymph node/bone marrow metastasis                                       | [77]       |
| Gastric cancer              | A majority of primary gastric tumors and many human gastric carcinoma cell lines express CXCR4. Primary tumors that express CXCR4 protein are associated with peritoneal carcinomatosis | [78]       |
| Head and neck squamous cell cancer | CXCR4 expression is found in tissues and cell lines. High CXCR4 expression is associated with increased occurrence of distant metastases and reduced survival | [79, 80]   |
| Hepatocellular carcinoma    | CXCR4 is correlated with tumor progression, metastasis, and reduced survival                                                               | [81]       |
| Melanoma                    | CXCR4 protein is expressed on human melanoma cell lines, as well as on cells isolated from melanoma surgical specimens. CXCL12 enhances cell adhesion to fibronectin, the binding of murine melanoma cells to endothelial cells, and invasion of human melanoma cells across basement membranes. CXCR4 expression is associated with reduced disease-free survival and overall survival | [35, 43, 82, 83]|
| Multiple myeloma            | Multiple myeloma cells isolated from bone marrow and multiple myeloma cell lines express cell-surface CXCR4 protein. CXCL12 enhances adhesion to fibronectin and stimulates cell migration | [84]       |
| Cancer                          | Comments                                                                                                                                                                                                 | References       |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Nasopharyngeal cancer          | Most primary human nasopharyngeal carcinoma biopsy samples and metastatic lymph nodes stain positively for CXCR4 protein. Nasopharyngeal carcinoma cell lines also express CXCR4 mRNA.                                      | [85]             |
| Non-Hodgkin's lymphoma         | Most tissue samples and cell lines express high levels of CXCR4 mRNA and cell-surface protein. CXCR4 is implicated in transendothelial migration and proliferation of non-Hodgkin’s lymphoma cells.                                      | [86]             |
| Nonmelanoma skin cancer        | CXCR4 is expressed on invasive squamous cell carcinoma and basal cell carcinoma tissues. Expression on invasive squamous cell carcinoma is increased compared to normal skin.                                             | [87]             |
| Non-small cell lung cancer     | CXCR4 mRNA is upregulated in NSCLC tissues compared to normal tissues, and levels are higher in tissue samples taken from patients with metastasis than from those without metastasis. Overexpression of CXCR4 in NSCLC cells leads to enhanced migratory, invasive, and adhesive responses to CXCL12. Nuclear CXCR4 staining is associated with longer survival and reduced incidence of metastasis. | [88, 89]         |
| Osteosarcoma                   | CXCR4 mRNA is expressed in most human osteosarcoma samples, and two of three osteosarcoma cell lines. CXCR4 expression is higher at metastatic sites than in the primary tumor.                                                        | [90, 91]         |
| Ovarian cancer                 | CXCR4 mRNA is expressed in ovarian cancer cell lines, as well as in biopsies from primary tumors and ovarian cancer ascites. High levels of CXCL12 are present in ascitic fluid taken from patients with ovarian cancer. CXCL12 stimulates the growth of ovarian cancer cells. CXCR4 expression is associated with increased recurrence and reduced survival. | [26, 33, 92]     |
| Pancreatic cancer              | Most human pancreatic cancer tissues stain positively for CXCR4 expression, and more than half of pancreatic cancer cell lines express CXCR4 mRNA and cell-surface protein. CXCL12 induces chemotaxis of human pancreatic carcinoma cells, as well as stimulates proliferation and promoted survival. | [42, 93]         |
| Prostate cancer                | Prostate cancer cell lines express CXCR4 mRNA and protein, and approximately half of prostate cancer tissues stain positively for CXCR4. Treatment of cells with CXCL12 increases their adherence to osteosarcoma cells and bone marrow endothelial cells, transendothelial migration, and invasion into Matrigel. CXCR4 expression is a positive predictor of bone metastasis, particularly in patients with elevated prostate specific antigen (PSA) levels. High CXCR4 expression is associated with increased cancer-specific mortality. | [29, 36, 94, 95] |
| Renal cell cancer              | One of four human renal cell cancer lines express CXCR4 mRNA, which is upregulated in renal cell cancer tumor samples compared to normal tissue. High CXCR4 expression is associated with poor tumor-specific survival, independent of tumour stage and differentiation grade. | [96, 97]         |
| Rhabdomyosarcoma               | Several rhabdomyosarcoma cell lines express cell-surface CXCR4 protein. CXCL12 increases cell motility, induces chemotaxis, increases adhesion to extracellular matrix, and stimulates secretion of MMP-2.                                             | [37]             |
| Small cell lung cancer         | CXCR4 mRNA and cell-surface protein are detected in cell lines. CXCL12 induces proliferation, increases adherence and motility, and induces morphological changes such as filopodia formation.                                      | [98]             |
| Thyroid cancer                 | Human thyroid carcinoma cell lines express CXCR4 protein, and CXCR4 is upregulated in primary papillary thyroid carcinomas compared to normal thyroid tissue. CXCL12 increases proliferation, inhibits apoptosis, and increases migration and invasion of human thyroid cancer cells. | [99, 100]        |
8. CXCR4 IN COLORECTAL CANCER

CXCR4 is abundantly expressed by colorectal carcinoma cells [104, 105]. The involvement of CXCR4 expression in colorectal cancer progression was first shown by Roos and colleagues [71]. CT-26 mouse colon carcinoma cells were transfected with CXCL12 extended with a Lys-Asp-Glu-Leu (KDEL) sequence. The KDEL receptor functions to retain resident endoplasmic reticulum (ER) proteins, which contain a C-terminal KDEL sequence, in the ER. With this “intrakine approach,” CXCL12-KDEL binds to the KDEL receptor and is retained in the ER, and CXCR4 protein which binds to CXCL12 is also retained in the ER, preventing its expression at the cell-surface [71, 106]. This approach was first developed as a strategy to reduce HIV infection [107]. After intrasplenic injection, CXCL12-KDEL-transfected CT-26 cells, which had reduced cell-surface CXCR4 protein expression, did not form liver metastases, whereas control cells did [71]. The incidence of lung metastasis was also reduced with CXCL12-KDEL-transfected cells, and survival was increased. Interestingly, unlike Zlotnik’s group, who had suggested that CXCR4 expression was necessary for the movement of tumor cells to secondary sites [25], Zeelenberg and colleagues found that CXCR4 expression was not required for migration of CT-26 colorectal tumor cells to the lungs, but rather for tumor expansion at secondary sites [71]. Therefore, these authors concluded that CXCR4 is necessary for the outgrowth of colon cancer micrometastases.

Ottaiano and colleagues found that CXCR4 was overexpressed in human colorectal carcinoma tissues compared to normal tissues [40]. Cell-surface CXCR4 protein was also expressed at high levels on SW620, SW48, and SW480 colorectal carcinoma cells, and at moderate levels on Caco-2 and LoVo cells. CXCL12 enhanced the chemotaxis of SW480 cells as well as their adhesion to fibronectin and collagen type I/III, and both effects were blocked with an anti-CXCR4 neutralizing antibody. CXCL12 also induced cytoskeletal changes, proliferation, and ERK1/2 phosphorylation in SW480 cells. Similarly, Schimanski and colleagues found that SW480, SW620, and HT-29 colorectal carcinoma cells expressed CXCR4 protein, as did colorectal carcinoma tissue samples [72]. CXCL12 induced the chemotaxis of SW480 and SW620 cells. Kim and colleagues found that in patients with colorectal cancer with liver metastases, higher CXCR4 expression was found on metastatic tissues compared to the primary tumor [73]. Furthermore, elevated CXCR4 expression in colorectal cancer is associated with disease progression and reduced survival [40, 72, 73, 75].

9. THE UTILITY OF CXCR4 AS A MARKER OF TUMOR PROGRESSION

CXCR4 expression has been associated with disease progression, increased recurrence, and reduced survival in many cancer types, as listed in Table 1. As pointed out earlier, CXCR4 protein expression is detectable in the majority of cases of DCIS of the breast, whereas CXCR4 levels are very low in adjacent normal breast epithelium [46]. This suggests that the acquisition of CXCR4 expression may occur very early in malignant transformation, suggesting its potential as a biomarker. As indicated earlier, it has been suggested that CXCR4 expression may be useful as an indicator of prognosis [56, 73].

Although mutations in the CXCR4 gene have not been reported in the context of cancer, patients with a single nucleotide polymorphism in the 3′ untranslated region of the CXCL12 gene had reduced incidence of long distance metastasis of epidermoid non-small cell lung cancer (NSCLC) [108].

10. PRECLINICAL EFFICACY OF ANTI-CXCR4 TREATMENTS

Several studies have demonstrated the efficacy of strategies designed to reduce CXCR4 expression or inhibit its activity in preclinical models of cancer development and metastasis. A neutralizing anti-CXCR4 antibody prevented metastasis of MDA-MB-231 breast cancer cells in mice [25] and in another study reduced tumor growth after intraperitoneal (IP) injection of Namalwa non-Hodgkin’s lymphoma cells [86]. Interestingly, a neutralizing antibody against CXCR4 also inhibited the growth of subcutaneous tumors derived from pancreatic cancer cells that did not themselves express
CXCR4, probably because of the ability of the antibody to block CXCR4 on tumor vasculature [109].

CXCR4 peptide antagonists have also proven effective in preclinical cancer models. The CXCR4 peptide antagonist 4F-benzoyl-TN14003 inhibited lung metastasis of MDA-MB-231 breast cancer cells [110], and 4F-benzoyl-TE14011 reduced pulmonary metastasis of B16-BL6 melanoma cells [111]. Murakami and colleagues assessed the contribution of CXCR4 to the metastatic process by transducing B16 murine melanoma cells with CXCR4, followed by IV injection in syngeneic B57BL/6 mice [112]. CXCR4 expression in this context led to increased pulmonary metastasis, which was reduced with the CXCR4 peptide antagonist T22. Liang and colleagues showed that TN14003 itself, which is a 14-mer peptide CXCR4 antagonist, inhibited in vitro invasion of MDA-MB-231 breast cancer cells and lung metastasis after tail vein injection of these cells, without causing any toxicity [113].

Small molecule (nonpeptide) inhibitors of CXCR4 have also been tested in preclinical cancer models. Rubin and colleagues showed that the noncompetitive CXCR4 antagonist AMD3100 inhibited tumor growth after intracranial implantation of Daoy medulloblastoma cells and U87 glioblastoma cells [63] and also inhibited peritoneal carcinomatosis and ascites formation after IP inoculation of NUGC4 human gastric carcinoma cells [78]. In a different approach, blocking the mammalian target of rapamycin (mTOR) pathway downstream of CXCR4 was shown to suppress processes involved in the peritoneal dissemination of gastric cancer [114].

Liang and colleagues also showed the preclinical efficacy of anti-CXCR4 treatments using an RNA-silencing molecular approach [115]. MDA-MB-231 breast cancer cells transfected with siRNA oligonucleotides to knock down CXCR4 were injected into the tail veins of SCID mice. Mice received twice-weekly IV injections of siRNA oligonucleotides to maintain CXCR4 knockdown. The control mice all developed lung metastases, whereas only one of six mice receiving CXCR4 siRNA-transfected cells and followup injections with CXCR4 siRNA developed metastases. Stable knockdown of CXCR4 expression in 4T1 murine breast carcinoma cells using short hairpin RNA reduced orthotopic tumor growth and lung metastasis [49]. Similarly, MDA-MB-231 cells that had undergone stable knockdown of CXCR4 did not form tumors or lung metastases after orthotopic injection into mammary fat pads of SCID mice, whereas CXCR4-positive cells were tumorigenic [116]. NSCLC 95D lung cancer cells in which CXCR4 was knocked down using antisense technology also formed lung metastases in fewer mice after SC injection compared to CXCR4 positive cells [88]. Finally, manipulations of CXCR4 expression have become possible using microRNAs (miRNAs), which are endogenous short RNAs with the ability to repress the translation of target mRNAs [117–119]. The approach of expressing a synthetic miRNA against CXCR4 mRNA to knock down CXCR4 expression has been used successfully in MDA-MB-231 breast cancer cells, HeLa cervical carcinoma cells, and U2-OS osteosarcoma cells [118, 120, 121]. Reduced CXCR4 expression in the breast cancer model was accompanied by reduced migration and invasion of the cells in vitro and fewer lung metastases in vivo [121]. These studies show the importance of CXCR4 expression in both primary and secondary tumor growth.

11. CLINICAL ASSESSMENT OF CXCR4-TARGETED REAGENTS

The bicyclam compound AMD3100 was developed as a small molecule CXCR4 antagonist [122]. Although this compound has not yet been fully assessed in clinical trials to determine its therapeutic potential in cancer, it has been examined in small trials in the context of HIV treatment and hematopoietic progenitor cell mobilization [123–128]. One trial with AMD3100 reported one patient with thrombocytopenia, two patients with premature ventricular contractions, and several patients with paresthesias [126]. AMD3100 did not reduce viral load in HIV patients [122], but did effectively increase hematopoietic progenitor cell mobilization [124, 125, 127, 128]. However, the mechanisms of action are under debate and may be unrelated to inhibition of CXCR4 as was first presumed.

12. REGULATION OF CXCR4 EXPRESSION BY FACTORS WITHIN THE TUMOR

Zeelenberg and colleagues found that CT-26 murine colon carcinoma cells grown in vitro expressed CXCR4 mRNA, but cell-surface protein levels were not detectable [71]. When the same cells were freshly isolated from lung or liver metastases or from intrasplenic tumors, cell-surface expression was strongly upregulated. This elevated expression was lost after 2–4 days in culture, indicating that it was not due to selection of a subpopulation of cells with a high CXCR4 expression. The authors concluded that CXCR4 expression was induced by the in vivo tumor microenvironment. Although others have shown that metastatic cells maintain high CXCR4 expression when cultured in vitro [129], and indeed CXCR4 has been suggested as a cancer stem cell biomarker [130], as discussed below there is substantial evidence indicating that CXCR4 expression is nevertheless influenced by the tumor microenvironment. Additionally, aberrant activation of signaling pathways within cancer cells, such as those initiated through HER2, can also contribute to elevated CXCR4 expression [131].

Multiple features and factors present in the tumor microenvironment have been shown to regulate CXCR4 expression on tumor cells and other cell types. One such feature is hypoxia [97, 132]. Solid tumors tend to be hypoxic due to structural abnormalities in their vasculature [133]. Staller and colleagues were the first to demonstrate the involvement of hypoxia in the regulation of CXCR4 expression [97]. Their goal was to identify genes regulated by the von Hippel-Lindau tumor suppressor protein (pVHL) in renal cell carcinoma cells. pVHL is often inactivated in renal cell cancer (RCC) leading to constitutive activation of hypoxia-inducible factor-1 (HIF-1) target genes. In a microarray analysis, they found that CXCR4 mRNA expression was suppressed by the reintroduction of functional
pVHL into pVHL-deficient A498 RCC cells, an effect that was due to inactivation of HIF-1. CXCR4 protein was also downregulated, resulting in reduced migration of RCC cells towards CXCL12. Hypoxia increased CXCR4 mRNA expression in HEK-293 human embryonic kidney cells and primary human proximal renal tubular epithelial cells, and a hypoxia response element (HRE) was identified within the CXCR4 promoter [97]. The authors speculated that intratumoral hypoxia may lead to increased CXCR4 expression in diverse types of solid tumors, increasing metastasis to distant organs. Shioppa and colleagues found that hypoxia increased CXCR4 mRNA and cell-surface protein expression in several cell types, including monocytes, human monocyte-derived macrophages, tumor-associated macrophages, HUVECs, CAOV3 ovarian carcinoma cells, and MCF-7 breast carcinoma cells, leading to increased migration towards CXCL12 due to the activation of HIF-1α [132].

The hypoxic environment within tumors also leads to high extracellular levels of adenosine (adenine-9-β-D-ribofuranoside), a nucleoside that is involved in energy metabolism and comprises the core structure for adenine nucleotides. The concentration of adenosine in the extracellular fluid of solid tumors is about 100-fold that of adjacent normal tissue [134]. Adenosine concentrations in tumors reach levels that can act on any of four subtypes of adenosine-selective, G-protein-coupled receptors: A1, A2a, A2b, and A3 [135]. Adenosine receptors of all four known subtypes are expressed differentially on different cell types within the tumor, including stromal cells, endothelial cells, and infiltrating leukocytes. We have shown that through such receptors, adenosine can have protumor effects directly on cancer cells and also indirectly via other supporting/infiltrating cells [136–139]. Adenosine also acts through A2a and A2b adenosine receptors on human colorectal carcinoma cells to upregulate CXCR4 mRNA expression up to 10-fold, and selectively increase cell-surface CXCR4 protein up to 3-fold [31]. This increase in cell-surface CXCR4 enables the carcinoma cells to migrate toward CXCL12 and enhances their proliferation in response to CXCL12.

One of the further major factors that allows tumor expansion is vascular endothelial growth factor (VEGF), which is also produced in response to hypoxia and which promotes neovascularisation of the tumor. The angiogenic effect of VEGF increases the supply of nutrients and blood-borne growth factors to allow growth of the tumor. There is significant interplay between the roles of VEGF and CXCR4 in tumor expansion. Concomitant high expression of CXCR4 and VEGF has been observed in colorectal [74, 75], breast [38], and ovarian [34] cancers, as well as in glioma [140] and osteosarcoma [91], in each of which it has been linked to increased angiogenesis, invasion, and/or metastasis. Clinical studies have shown that although VEGF and CXCR4 both predispose to lymphatic involvement and nodal metastasis in colorectal cancer, they work through different regulatory strategies [74]. Their collaborative role in angiogenesis parallels a similar joint action in noncancer processes involving neovascularisation (e.g., [141]), and it has been suggested in the context of tumor angiogenesis that their actions may be synergistic [34]. It is not surprising that these two entities are closely linked; VEGF receptors and CXCR4 have common regulatory pathways. For example, interference with Notch signalling leads to downregulation of both VEGF receptor 2 and CXCR4 [142].

The relationship between VEGF and CXCR4 is complex. Firstly, VEGF can promote CXCR4 pathways. VEGF is present in high levels in tumors and may upregulate CXCR4 expression in tumor cells, as has been demonstrated in glioma [143] and breast cancer [144]. In the case of tumor cells, this upregulation of CXCR4 by VEGF can happen through an autocrine mechanism [144]. VEGF can also upregulate CXCR4 on the endothelial cells that may be involved in angiogenesis during tumor expansion [145, 146].

Conversely, the ability of CXCR4 to signal through PI3K/Akt and ERK1/2 provides a route through which VEGF expression may be regulated by CXCR4 [147–149]. Binding of CXCL12 to CXCR4 has been shown to increase cellular secretion of VEGF in ovarian cancer [150], breast cancer [147], prostate cancer [149, 151], and malignant glioma [152]. This phenomenon parallels the ability of the CXCL12/CXCR4 axis to stimulate VEGF secretion in normal lymphohematopoietic cells [153]. One might therefore expect a large part of the multitumor activity of CXCR4 antagonists to be mediated through reduced secretion of VEGF. Indeed, interference with the CXCL12-CXCR4 pathway has been shown to cause downregulation of expression of VEGF [39]. However, blocking the CXCL12/CXCR4 axis in vivo can inhibit tumor growth and angiogenesis without producing alterations in VEGF pathways [109].

Other growth factors whose levels are elevated in tumors may also enhance CXCR4-dependent mechanisms. Tumors have high levels of tumor necrosis factor-α (TNF-α), derived primarily from tumor-associated macrophages (TAMs) [154–156]. TNF-α itself, or macrophages that serve as a source of TNF-α, are able to increase CXCR4 mRNA and cell-surface protein expression on ovarian cancer cells [157] and astrogloma cells [158]. A significant correlation between TNF-α and CXCR4 expression was found in ovarian cancer biopsies [157]. The increase in CXCR4 at a cellular level appears to be due to TNF-α-induced activation of NF-κB signaling and is associated with enhanced migration towards CXCL12 [157]. Therefore, TAMs may contribute to increased CXCR4 expression on cancer cells via production of TNF-α.

Finally, polypeptide growth factors that are associated with the extracellular matrix, and indeed components of the extracellular matrix itself, can upregulate CXCR4 on cancer cells. Transforming growth factor-β (TGF-β) increases cell-surface CXCR4 protein expression on human melanoma cells [35] and we have recently found that FGF-2 upregulates CXCR4 on human colorectal cancer cells (Bosco B and Blay J, manuscript in preparation). Furthermore, type-I collagen and the preparation Matrigel, which is a secreted ECM rich in laminin [159], also increase levels of CXCR4 on melanoma cells [35]. Therefore, interactions with matrix proteins within tumors may also increase CXCR4 expression.
Membrane phospholipids

| Arachidonic acid | Phospholipase A<sub>2</sub> |
|------------------|--------------------------|
| PGG<sub>2</sub>/PGH<sub>2</sub> | Cyclooxygenases |
| PGD<sub>2</sub> | PGD synthase |
| PGJ<sub>2</sub> (Non-enzymatic conversion) |
| Δ12-PGJ<sub>2</sub> |
| 15dPGJ<sub>2</sub> |

**Figure 1:** Production of PGD<sub>2</sub> and conversion to its metabolites. Prostanoids follow an initial common pathway in which arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub> and then converted to the short-term intermediates PGG<sub>2</sub> and PGH<sub>2</sub> by cyclooxygenases. Prostaglandin D synthase forms PGD<sub>2</sub> itself, but subsequent nonenzymatic reactions in aqueous media lead to the sequential production of prostaglandin J<sub>2</sub> (PGJ<sub>2</sub>), 9-deoxy-Δ<sub>9</sub>,Δ<sub>12</sub>-13,14-dihydro-PGD<sub>2</sub> (Δ<sub>12</sub>-PGJ<sub>2</sub>), and 15-deoxy-Δ<sub>10</sub>,14-PGJ<sub>2</sub> (15dPGJ<sub>2</sub>).
Furthermore, the end metabolite 15dPGJ$_2$ is active against many cell types, including colorectal carcinoma cells [191, 192], prostate carcinoma cells [193], and Burkitt lymphoma cells [194], suggesting that 15dPGJ$_2$ may be the crucial mediator.

16. THE ROLE OF 15dPGJ$_2$ AND ITS ACTION ON PPAR$_\gamma$

15dPGJ$_2$ is an agonist for the nuclear receptor peroxisome proliferator-activated receptor $\gamma$ (PPAR$_\gamma$) [196, 197], and activation of PPAR$_\gamma$ may account for the growth inhibitory effects of 15dPGJ$_2$. PPAR$_\gamma$ activation results in its heterodimerization with the retinoid X receptor (RXR), binding to peroxisome proliferator response elements (PPREs) on DNA, and subsequent activation of target gene expression [198]. PPAR$_\gamma$ is aberrantly expressed in some cancer types [199], and in many cases its activation leads to cell death or differentiation [191, 200, 201]. This action of 15dPGJ$_2$, and by extension its precursors PGD$_2$, PGE$_2$, and $\Delta^{12}$-PGJ$_2$, may underlie the major action of these eicosanoids on cell growth. For example, 15dPGJ$_2$ reduces the growth of PC-3 human prostate cancer cells through the activation of PPAR$_\gamma$ [202]. However, in addition to direct growth-inhibitory effects, 15dPGJ$_2$ may also exert anticancer effects by reducing expression of protumor proteins. For example, 15dPGJ$_2$ inhibits phorbol ester-induced VEGF and COX-2 expression in SW620 human colorectal carcinoma cells [203].

17. 15dPGJ$_2$ CAUSES DOWNREGULATION OF CXCR4 ON CANCER CELLS

In our studies of the possible effects of these different prostaglandins on CXCR4, we focused upon the expression of the mature protein and furthermore restricted our quantitation exclusively to the receptor that is displayed to the external environment at the cell surface [31]. Cell-surface CXCR4 reflects functional receptor that is coupled to cellular responses [31] rather than the very large intracellular pool of inaccessible receptor protein [72].

Although PGF$_{2\alpha}$ (to some extent) and PGE$_2$ (as well as its product PGG$_2$) have some ability to modulate CXCR4 levels, by far the most potent prostaglandins in this regard are PGD$_2$ and its derivatives [204]. Prostaglandin D$_2$ and the J-series prostaglandins used at low micromolar concentrations cause substantial loss of CXCR4 from the surface of HT-29 human colorectal carcinoma cells [204]. In particular, 15dPGJ$_2$ completely eliminates cell-surface CXCR4 at a concentration of $10^{-5}$ M in vitro, and has significant effects after a single dose of 300 nM, about 100-fold less than for PGF$_{2\alpha}$ [204]. The time course of the decline in cell-surface CXCR4 protein is slow, reaching a maximum only after 48–72 hours (Figure 2). The concentrations of prostaglandins that are needed to cause downregulation after a single dose likely grossly overestimate the steady-state levels that would cause such a response, as we have found in other studies with labile metabolites [31, 138]. We estimate that the effect of 15dPGJ$_2$ on CXCR4 is achievable with concentrations of 15dPGJ$_2$ present in vivo.

![Figure 2: Time course of changes in cell-surface CXCR4 protein expression on HT-29 cells by PGD$_2$ and its metabolites. HT-29 cells were treated with vehicle or with 10$\mu$M PGD$_2$ (light gray bars), 10$\mu$M PGJ$_2$ (dark gray bars), or 3$\mu$M 15dPGJ$_2$ (hatched bars), and cell-surface CXCR4 protein expression was measured at the indicated time points. The data shown are expressed relative to the level of CXCR4 receptor on cells treated with vehicle alone at that time point. Values have also been corrected for any possible changes in cell number. The data are mean values ± SE ($n = 4$). Significant decrease due to prostaglandin, **$P < .01$; *$P < .05$. The figure is taken from [204] with permission.](image)

As can be seen in Figure 2, the response to 15dPGJ$_2$ occurs more rapidly than that to PGJ$_2$, which in turn has a more rapid onset than PGD$_2$. We further found that each of these prostaglandins does suppress CXCR4 mRNA expression and that the effect of 15dPGJ$_2$ again occurs earlier than that of PGD$_2$ [204]. The different relative kinetics of the downregulation of CXCR4 for the J-series prostaglandins are consistent with data on the conversion of PGD$_2$ through to 15dPGJ$_2$ [189] pointing to 15dPGJ$_2$ as the key factor in controlling the levels of functional CXCR4. PGD$_2$ produces similar downregulation of CXCR4 in other cell types such as the T47D human breast carcinoma cell line (Richard CL, Blay J, unpublished observations), suggesting that this may be a common phenomenon. The downregulation of CXCR4 expression by 15dPGJ$_2$ differs from 15dPGJ$_2$-mediated downregulation of other proteins, including cyclin D1 and estrogen receptor $\alpha$, which has been shown to occur through protein degradation rather than through changes in transcription [205].

18. 15dPGJ$_2$ DOWNREGULATES CXCR4 PRIMARILY VIA PPAR$_\gamma$

The main target for 15dPGJ$_2$ is the nuclear receptor PPAR$_\gamma$ [196, 197]. We found that the ability of 15dPGJ$_2$ to down-regulate CXCR4 occurred primarily through this pathway. The effect of 15dPGJ$_2$ was mimicked by PPAR$_\gamma$ agonists such as rosiglitazone (Table 2, [206]), and antagonized or blocked by the PPAR$_\gamma$ antagonists GW9662 and T0070907.
and may impede metastasis. Levels of its precursor PGD2 are low in tissues of familial adenomatous polyposis, a condition that predisposes to colorectal cancer [172], and have been negatively correlated with hepatic metastasis in tumor tissues taken from patients with colorectal cancer [188]. The enzyme involved in PGD2 synthesis, PGD synthase (PGDS), is decreased in cerebrospinal fluid of brain cancer patients compared to patients without disease [214]. There is a contested report of levels of 15dPGJ2 being decreased during breast cancer progression, with the lowest levels being detected in metastatic disease [173]. Finally, mechanisms to sequester or eliminate 15dPGJ2 may be upregulated in cancer [215, 216]. Overall, it seems that the predominant prostaglandin within tumors is PGE2, and 15dPGJ2 may not be present in high levels at all. Thus, 15dPGJ2-dependent suppression of CXCR4 seems to be a restraint mechanism that is not operative in a cancer situation.

**19. SYNTHETIC PPARγ AGONISTS DOWNREGULATE CXCR4 ON CANCER CELLS**

As indicated above, the PPARγ agonist rosiglitazone also decreased CXCR4 expression on human colorectal cancer cells, congruent with an effect of 15dPGJ2 through PPARγ. This effect was seen at both the mRNA and protein level, and was more durable than the effect of 15dPGJ2, as it would be expected for a more chemically stable ligand [101, 204]. Moreover, we found that other glitazone agents also downregulate CXCR4, with a rank order of potency (rosiglitazone > pioglitazone > ciglitazone > troglitazone) consistent with their potencies for interaction with PPARγ [206, 217, 218]. Further confirming that these agents were acting through their expected target, PPARγ, and that this target is linked to elimination or reduction of CXCR4 at the cell surface, we showed that the ability of rosiglitazone to decrease CXCR4 was blocked by the PPARγ antagonists GW9662 and T0070907 (Table 2), or by shRNA knockdown of PPARγ expression in the cancer cells [101].

Therefore, rosiglitazone and its analogues act through PPARγ to cause substantial and persistent suppression of CXCR4 on cancer cells. Since these agents are the same chemicals as the thiazolidinedione (TZD) class of drugs that have been used clinically for the treatment of diabetes (although recent concerns regarding side effects have limited...
their utility, it opens up the possibility that we may already have a means to manipulate CXCR4 levels in cancer. Given that CXCR4 expression is linked to metastasis, judicious use of TZDs may allow us an opportunity to influence the metastatic process (Figure 3). Recent studies have shown that a unique population of CXCR4+ stem cells may be crucial for expansion of tumor cell populations [130]. We suggest that TZD therapy, by stimulating PPARγ-dependent downregulation of CXCR4 on cancer cells, may slow the rate of metastasis and may impact beneficially on disease progression.

ABBREVIATIONS

CAY10410: 9,10-dihydro-15-deoxy-Δ12,14-prostaglandin J2
CXCL12: CXC chemokine ligand 12
CXCR4: CXC chemokine receptor 4
DCIS: Ductal carcinoma in situ
GW9662: 2-chloro-5-nitro-N-phenylbenzamide
HIF-1: Hypoxia-inducible factor-1
HRE: Hypoxia response element
LESTR: Leukocyte-expressed seven-transmembrane domain receptor
NF-κB: Nuclear factor-κB
NSAIDs: Nonsteroidal anti-inflammatory drugs
NSCLC: Non-small cell lung cancer
PPARγ: Peroxisome proliferator-activated receptor γ
PPRE: Peroxisome proliferator response element
pVHL: Von Hippel-Lindau tumor suppressor protein
RCC: Renal cell cancer
RRX: Retinoid X receptor
SDF-1: Stromal cell-derived factor 1
T0070907: 2-chloro-5-nitro-N-(4-pyridyl)benzamide
TAM: Tumor-associated macrophages
VEGF: Vascular endothelial growth factor
15dPGJ2: 15-deoxy-Δ12,14-PGJ2
15-PGDH: 15-hydroxyprostaglandin dehydrogenase
Δ12-PGJ2: 9-deoxy-Δ8,Δ12,13,14-dihydro-PGD2.

ACKNOWLEDGMENTS

This work was supported by grants to Jonathan Blay from the Natural Sciences and Engineering Research Council of Canada (NSERC), and the Canadian Institutes for Health Research (CIHR); and by studentship awards to Cynthia Lee from NSERC, the Killam Foundation, and Cancer Care Nova Scotia.

REFERENCES

[1] K. Balabanian, B. Lagane, S. Infantino, et al., “The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes,” The Journal of Biological Chemistry, vol. 280, no. 42, pp. 35760–35766, 2005.
[2] P. M. Murphy, M. Baggiolini, I. F. Charo, et al., “International union of pharmacology. XXII. Nomenclature for chemokine receptors,” Pharmacological Reviews, vol. 52, no. 1, pp. 145–176, 2000.
[3] M. Mellado, J. M. Rodriguez-Frade, S. Mañes, and C. Martínez-A, “Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation,” Annual Review of Immunology, vol. 19, pp. 397–421, 2001.
[4] D. Rossi and A. Zlotnik, “The biology of chemokines and their receptors,” Annual Review of Immunology, vol. 18, pp. 217–243, 2000.
[5] S. M. Foord, T. I. Bonner, R. R. Neubig, et al., “International Union of Pharmacology. XLVI. G protein-coupled receptor list,” Pharmacological Reviews, vol. 57, no. 2, pp. 279–288, 2005.
[6] M. Loetscher, T. Geiser, T. O’Reilly, R. Zwahlen, M. Baggiolini, and B. Moser, “Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes,” The Journal of Biological Chemistry, vol. 269, no. 1, pp. 232–237, 1994.
[7] Y. Feng, C. C. Broder, P. E. Kennedy, and E. A. Berger, “HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor,” Science, vol. 272, no. 5263, pp. 872–877, 1996.
[8] C. C. Bleul, M. Farzan, H. Choe, et al., “The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,” Nature, vol. 382, no. 6594, pp. 829–833, 1996.
[9] E. Oberlin, A. Amara, F. Bacherelie, et al., “The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1,” Nature, vol. 382, no. 6594, pp. 833–835, 1996.
[10] A. Caruz, M. Samsom, J. M. Alonso, et al., “Genomic organization and promoter characterization of human CXCR4 gene,” FEBS Letters, vol. 426, no. 2, pp. 271–278, 1998.
[11] S. A. Wegner, P. K. Ehrenberg, G. Chang, D. E. Dayhoff, A. L. Sleeker, and N. L. Michael, “Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1,” The Journal of Biological Chemistry, vol. 273, no. 8, pp. 4754–4760, 1998.
[12] L. Zhang, T. He, A. Talal, G. Wang, S. S. Frankel, and D. D. Ho, “In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR5, AND CCR3,” Journal of Virology, vol. 72, no. 6, pp. 5035–5045, 1998.
[13] F. Balkwill, “The significance of cancer cell expression of the chemokine receptor CXCR4,” Seminars in Cancer Biology, vol. 14, no. 3, pp. 171–179, 2004.
[14] M. Shirozu, T. Nakano, J. Inazawa, et al., “Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene,” Genomics, vol. 28, no. 3, pp. 495–500, 1995.
[15] T. Nagasawa, S. Hirota, K. Tachibana, et al., “Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1,” Nature, vol. 382, no. 6592, pp. 635–638, 1996.
[16] K. Tachibana, S. Hirota, H. Iizasa, et al., “The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract,” Nature, vol. 393, no. 6685, pp. 595–599, 1998.
[17] A. Aiuti, J. J. Webb, C. Bleul, T. Springer, and J.C. Gutierrez-Ramos, “The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides...
a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood," Journal of Experimental Medicine, vol. 185, no. 1, pp. 111–120, 1997.

[19] P. A. Hernandez, R. J. Gorlin, J. N. Lukens, et al., "Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease," Nature Genetics, vol. 34, no. 1, pp. 70–74, 2003.

[20] M. Kucia, R. Reca, K. Miekus, et al., "Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor-1/CXCR4 axis," Stem Cells, vol. 23, no. 7, pp. 879–894, 2005.

[21] J. Imirotola, K. Raddass, K. I. Park, et al., "CXCL12 and vascular endothelial growth factor synergistically induce neovangiogenesis in human ovarian cancers," Cancer Research, vol. 65, no. 20, pp. 6790–6798, 2005.

[22] J. Libura, J. Drukala, M. Majka, et al., "CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion," Blood, vol. 100, no. 7, pp. 2597–2606, 2002.

[23] C. J. Scotton, J. L. Wilson, D. Milliken, G. Stamp, and E. R. Balkwill, "Epithelial cancer cell migration: a role for chemokine receptors?" Cancer Research, vol. 61, no. 13, pp. 4961–4965, 2001.

[24] R. A. Moyer, M. K. Wendt, P. A. Johannesen, J. R. Turner, and M. B. Dwinell, "Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia," Laboratory Investigation, vol. 87, no. 8, pp. 807–817, 2007.

[25] A. Müller, B. Homey, H. Soto, et al., "Involvement of chemokine receptors in breast cancer metastasis," Nature, vol. 410, no. 6824, pp. 50–56, 2001.

[26] M. Kato, J. Kitayama, S. Kazama, and H. Nagawa, "The effect of anti-CXCR4 antibodies on human colon cancer cells," Cancer Immunology, Immunotherapy, vol. 54, no. 8, pp. 620–625, 2005.

[27] R. S. Taichman, C. Cooper, E. T. Keller, K. J. Pienta, N. S. Taichman, and L. K. McCauley, "Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone," Cancer Research, vol. 62, no. 6, pp. 1832–1837, 2002.

[28] C. H. Tang, J. Y. Chuang, Y. C. Fong, M. G. Maa, T. D. Way, and C. H. Hung, "Bone-derived SDF-1 stimulates IL-6 Release via CXCR4, ERK and NF-kB pathways and promoting osteoclastogenesis in human oral cancer cells," Carcinogenesis. In press.

[29] C. L. Richard, E. Y. Tan, and J. Blay, "Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1α," International Journal of Cancer, vol. 119, no. 9, pp. 2044–2053, 2006.

[30] Y.-X. Sun, J. Wang, C. E. Shelburne, et al., "Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo," Journal of Cellular Biochemistry, vol. 89, no. 3, pp. 462–473, 2003.

[31] C. J. Scotton, J. L. Wilson, K. Scott, et al., "Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer," Cancer Research, vol. 62, no. 20, pp. 5930–5938, 2002.
A. Zlotnik, “Chemokines and cancer,” International Journal of Cancer, vol. 84, no. 3, pp. 247–250, 2004.

B. C. Schmid, M. Rudas, G. A. Rezniczek, S. Leodolter, and R. O. Salvucci, A. Bouchard, A. Baccarelli, et al., “The role of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival,” Neurosurgery, vol. 61, no. 3, pp. 570–579, 2007.

N. Cabioglu, J. Summy, C. Miller, et al., “CXCL12/stromal cell-derived factor-1α transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation,” Cancer Research, vol. 65, no. 15, pp. 6493–6497, 2005.

F. Andre, N. Cabioglu, H. Assi, et al., “Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer,” Annals of Oncology, vol. 17, no. 6, pp. 945–951, 2006.

H. Shim, S. K. Lau, S. Devi, Y. Yoon, H. T. Cho, and Z. Liang, “Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1α,” Biochemical and Biophysical Research Communications, vol. 346, no. 1, pp. 252–258, 2006.

J. Kodama, Hasengawa, T. Kusumoto, et al., “Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer,” Annals of Oncology, vol. 18, no. 1, pp. 70–76, 2007.

R. Möhle, C. Faienschmid, F. Bautz, and L. Kanz, “Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1),” Leukemia, vol. 13, no. 12, pp. 1954–1959, 1999.

N. Ishibe, M. Albitar, I. B. Jilani, L. R. Goldin, G. E. Marti, and N. E. Caporaso, “CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not,” Blood, vol. 100, no. 3, pp. 1100–1101, 2002.

I. S. Zeelenberg, L. Ruuls-Van Stalle, and E. Roos, “The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases,” Cancer Research, vol. 63, no. 13, pp. 3833–3839, 2003.

C. C. Schimanski, S. Schwald, N. Simiantonaki, et al., “Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer,” Clinical Cancer Research, vol. 11, no. 5, pp. 1743–1750, 2005.

J. Kim, H. Takeuchi, S. T. Lam, et al., “Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2744–2753, 2005.

S. Fukunaga, K. Maeda, E. Noda, T. Inoue, K. Wada, and K. Hirakawa, “Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer,” Oncology, vol. 71, no. 3–4, pp. 204–211, 2006.

A. Ottaiano, R. Franco, A. A. Talamanca, et al., “Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients,” Clinical Cancer Research, vol. 12, no. 9, pp. 2795–2803, 2006.

Y. Mizokami, H. Kajiyama, K. Shibata, K. Ino, F. Kikkawa, and S. Mizutani, “Stromal cell-derived factor-1α-induced cell
proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma,” *International Journal of Cancer*, vol. 110, no. 5, pp. 652–659, 2004.

[77] J. T. Kaifi, E. F. Yekebas, P. Schurr, et al., “Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer,” *Journal of the National Cancer Institute*, vol. 97, no. 24, pp. 1840–1847, 2005.

[78] K. Yasumoto, K. Koizumi, A. Kawashima, et al., “Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer,” *Cancer Research*, vol. 66, no. 4, pp. 2181–2187, 2006.

[79] A. Katayama, T. Ogino, N. Bandoh, S. Nonaka, and Y. Harabuchi, “Expression of CXCR4 and its down-regulation by IFN-γ in head and neck squamous cell carcinoma,” *Clinical Cancer Research*, vol. 11, no. 8, pp. 2937–2946, 2005.

[80] M. Taki, K. Higashikawa, S. Yoneda, et al., “Up-regulation of stromal cell-derived factor-1α and its receptor CXCR4 expression accompanied with epithelial-mesenchymal transition in human oral squamous cell carcinoma,” *Oncology Reports*, vol. 19, no. 4, pp. 993–998, 2008.

[81] C. C. Schimanski, R. Bahre, I. Gockel, et al., “Dissemination of CXCR4 predicts poor prognosis in patients with malignant melanoma,” *The Journal of Biological Chemistry*, vol. 276, no. 48, pp. 45098–45105, 2001.

[82] S. Scala, A. Otaiano, P. A. Ascierto, et al., “Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma,” *Clinical Cancer Research*, vol. 11, no. 5, pp. 1835–1841, 2005.

[83] F. Sanz-Rodríguez, A. Hidalgo, and J. Teixidó, “Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1,” *Blood*, vol. 97, no. 2, pp. 346–351, 2001.

[84] J. Hu, X. Deng, X. Bian, et al., “The expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells,” *Cancer Research*, vol. 65, no. 8, pp. 2937–2946, 2005.

[85] F. Bertolini, C. Dell’Agnola, P. Mancuso, et al., “CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin’s lymphoma,” *Cancer Research*, vol. 62, no. 11, pp. 3106–3112, 2002.

[86] J. Basile, B. Thiérs, J. Maize Sr., and D. M. R. Lathers, “Chemokine receptor expression in non-melanoma skin cancer,” *Journal of Cutaneous Pathology*, vol. 35, no. 7, pp. 623–629, 2008.

[87] L. Su, J. Zhang, H. Xu, et al., “Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells,” *Clinical Cancer Research*, vol. 11, no. 23, pp. 8273–8280, 2005.

[88] J.-P. Spano, F. Andre, L. Morat, et al., “Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome,” *Annals of Oncology*, vol. 15, no. 4, pp. 613–617, 2004.

[89] C. Laverdure, B. H. Hoang, R. Yang, et al., “Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma,” *Clinical Cancer Research*, vol. 11, no. 7, pp. 2561–2567, 2005.

[90] Y. Oda, H. Yamamoto, S. Tamiya, et al., “CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis,” *Modern Pathology*, vol. 19, no. 5, pp. 738–745, 2006.

[91] Y.-p. Jiang, X.-H. Wu, B. Shi, W.-X. Wu, and G.-R. Yin, “Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression,” *Gynecologic Oncology*, vol. 103, no. 1, pp. 226–233, 2006.

[92] T. Koshiba, R. Hosotani, Y. Miyamoto, et al., “Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression,” *Clinical Cancer Research*, vol. 6, no. 9, pp. 3530–3535, 2000.

[93] H. Mochizuki, A. Matsubara, J. Teishima, et al., “Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis,” *Biochemical and Biophysical Research Communications*, vol. 320, no. 3, pp. 656–663, 2004.

[94] T. Akashi, K. Koizumi, K. Tsuneyama, I. Saiki, Y. Takano, and H. Fuse, “Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer,” *Cancer Science*, vol. 99, no. 3, pp. 539–542, 2008.

[95] A. J. Schrader, O. Lechner, M. Templin, et al., “CXCR4/CXCL12 expression and signalling in kidney cancer,” *British Journal of Cancer*, vol. 86, no. 8, pp. 1250–1256, 2002.

[96] P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E. J. Oakeley, and W. Krek, “Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL,” *Nature*, vol. 425, no. 6955, pp. 307–311, 2003.

[97] T. Kijima, G. Mauilik, P. C. Ma, et al., “Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells,” *Cancer Research*, vol. 62, no. 21, pp. 6304–6311, 2002.

[98] J. H. Hwang, J. H. Hwang, H. K. Chung, et al., “CXCR chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 88, no. 1, pp. 408–416, 2003.

[99] M. D. Castellone, V. Guarino, V. De Falco, et al., “Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas,” *Oncogene*, vol. 23, no. 35, pp. 5958–5967, 2004.

[100] C. L. Richard and J. Blay, “Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner,” *International Journal of Oncology*, vol. 30, no. 5, pp. 1215–1222, 2007.

[101] C. A. Panabieres, J.-P. Brouillet, M. Fabbro, et al., “Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients,” *Journal of Immunological Methods*, vol. 299, no. 1–2, pp. 177–188, 2005.

[102] N. Cabiglioni, A. Sahin, M. Doucet, et al., “Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow,” *Clinical & Experimental Metastasis*, vol. 22, no. 1, pp. 39–46, 2005.

[103] N. J. Jordan, G. Kolios, S. E. Abbot, et al., “Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells,” *The Journal of Clinical Investigation*, vol. 104, no. 8, pp. 1061–1069, 1999.

[104] M. B. Dwinell, L. Eckmann, J. D. Leopard, N. M. Varki, and M. F. Kagnoff, “Chemokine receptor expression by human
intestinal epithelial cells,” *Gastroenterology*, vol. 117, no. 2, pp. 359–367, 1999.

[106] I. S. Zeelenberg, L. Ruuls-Van Stalle, and E. Roos, “Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma,” *The Journal of Clinical Investigation*, vol. 108, no. 2, pp. 269–277, 2001.

[107] J.-D. Chen, X. Bai, A.-G. Yang, Y. Cong, and S.-Y. Chen, “Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy,” *Nature Medicine*, vol. 3, no. 10, pp. 1110–1116, 1997.

[108] A. Coelho, C. Calzada, R. Catarino, D. Pinto, G. Fonseca, and R. Medeiros, “CXCL12-3’ A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?” *Cancer Immunology, Immunotherapy*, vol. 55, no. 6, pp. 639–643, 2006.

[109] B. Guleng, K. Tateishi, M. Ohta, et al., “Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner,” *Cancer Research*, vol. 65, no. 13, pp. 5864–5871, 2005.

[110] H. Tamamura, A. Hori, N. Kanzaki, et al., “T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer,” *FEBS Letters*, vol. 550, no. 1–3, pp. 79–83, 2003.

[111] M. Takenaga, H. Tamamura, K. Hiramatsu, et al., “A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma,” *Biochemical and Biophysical Research Communications*, vol. 320, no. 1, pp. 226–232, 2004.

[112] T. Murakami, W. Maki, A. R. Cardones, et al., “Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells,” *Cancer Research*, vol. 62, no. 24, pp. 7328–7334, 2002.

[113] Z. Liang, T. Wu, H. Lou, et al., “Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4,” *Cancer Research*, vol. 64, no. 12, pp. 4302–4308, 2004.

[114] I. Hashimoto, K. Koizumi, M. Tatematsu, et al., “Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells,” *European Journal of Cancer*, vol. 44, no. 7, pp. 1022–1029, 2008.

[115] Z. Liang, Y. Yoon, J. Votaw, M. M. Goodman, L. Williams, and H. Shim, “Silencing of CXCR4 blocks breast cancer metastasis,” *Cancer Research*, vol. 65, no. 3, pp. 967–971, 2005.

[116] N. Lapteva, A.-G. Yang, D. E. Sanders, R. W. Strube, and S.-Y. Chen, “CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo,” *Cancer Gene Therapy*, vol. 12, no. 1, pp. 84–89, 2005.

[117] J. G. Doench, C. P. Petersen, and P. A. Sharp, “siRNAs can function as miRNAs,” *Genes & Development*, vol. 17, no. 4, pp. 438–442, 2003.

[118] D. T. Humphreys, B. J. Westman, D. I. K. Martin, and T. Preiss, “MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 47, pp. 16961–16966, 2005.

[119] B. Wang, T. M. Love, M. E. Call, J. G. Doench, and C. D. Novina, “Recapitulation of short RNA-directed translational gene silencing in vitro,” *Molecular Cell*, vol. 22, no. 4, pp. 553–560, 2006.

[120] J. Liu, M. A. Valencia-Sanchez, G. J. Hannon, and R. Parker, “MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies,” *Nature Cell Biology*, vol. 7, no. 7, pp. 719–723, 2005.

[121] Z. Liang, H. Wu, S. Reddy, et al., “Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA,” *Biochemical and Biophysical Research Communications*, vol. 363, no. 3, pp. 542–546, 2007.

[122] E. De Clercq, “The bicyclam AMD3100 story,” *Nature Reviews Drug Discovery*, vol. 2, no. 7, pp. 581–587, 2003.

[123] C. W. Hendrix, C. Flexner, R. T. MacFarland, et al., “Pharmacokinetics and safety of AMD3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers,” *Antimicrobial Agents and Chemotherapy*, vol. 44, no. 6, pp. 1667–1673, 2000.

[124] S. M. Devine, N. Flomenberg, D. H. Vesole, et al., “Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma,” *Journal of Clinical Oncology*, vol. 22, no. 6, pp. 1095–1102, 2004.

[125] N. Flomenberg, S. M. Devine, J. F. DiPersio, et al., “The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone,” *Blood*, vol. 106, no. 5, pp. 1867–1874, 2005.

[126] C. W. Hendrix, A. C. Collier, M. M. Lederman, et al., “Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 37, no. 2, pp. 1253–1262, 2004.

[127] N. A. Lack, B. Green, D. C. Dale, et al., “A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100,” *Clinical Pharmacology & Therapeutics*, vol. 77, no. 5, pp. 427–436, 2005.

[128] W. C. Liles, E. Rodger, H. E. Broxmeyer, et al., “Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist,” *Transfusion*, vol. 45, no. 3, pp. 295–300, 2005.

[129] Y. Yoon, Z. Liang, X. Zhang, et al., “CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models,” *Cancer Research*, vol. 67, no. 15, pp. 7518–7524, 2007.

[130] P. C. Hermann, S. L. Huber, T. Herrler, et al., “Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer,” *Cell Stem Cell*, vol. 1, no. 3, pp. 313–323, 2007.

[131] Y. M. Li, Y. Pan, Y. Wei, et al., “Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis,” *Cancer Cell*, vol. 37, no. 3, pp. 348–442, 2005.

[132] T. Schioppa, B. Uranchimeg, A. Saccani, et al., “Regulation of the chemokine receptor CXCR4 by hypoxia,” *Journal of Experimental Medicine*, vol. 198, no. 9, pp. 1391–1402, 2003.

[133] P. Vaupel, “Tumor microenvironmental physiology and its implications for radiation oncology,” *Seminars in Radiation Oncology*, vol. 14, no. 3, pp. 198–206, 2004.

[134] J. Blay, T. D. White, and D. W. Hoskin, “The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine,” *Cancer Research*, vol. 57, no. 13, pp. 2602–2605, 1997.

[135] B. B. Fredholm, G. Arslan, L. Hallgren, B. Kull, G. Schulte, and W. Wasserman, “Structure and function of adenosine
receptors and their genes,” *Naunyn-Schmiedeberg’s Archives of Pharmacology*, vol. 362, no. 4-5, pp. 364–374, 2000.

[136] D. W. Hoskin, J. J. Butler, D. Drapeau, S. M. M. Haeryfar, and J. Blay, "Adenosine acts through an A₃ receptor to prevent the induction of murine anti-CD3-activated killer T cells,” *International Journal of Cancer*, vol. 99, no. 3, pp. 386–395, 2002.

[137] J. J. Butler, J. S. Mader, C. L. Watson, H. Zhang, J. Blay, and D. W. Hoskin, "Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways,” *Journal of Cellular Biochemistry*, vol. 89, no. 5, pp. 975–991, 2003.

[138] E. Y. Tan, M. Mujoomdar, and J. Blay, "Adenosine down-regulates the surface expression of dipetidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior,” *The American Journal of Pathology*, vol. 165, no. 1, pp. 319–330, 2004.

[139] E. Y. Tan, C. L. Richard, H. Zhang, D. W. Hoskin, and J. Blay, "Adenosine down-regulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway,” *American Journal of Physiology*, vol. 291, no. 3, pp. C433–C444, 2006.

[140] E. Maderna, A. Salmaggi, C. Calatoccozlo, L. Limido, and B. Pollo, "Nestin, PDGFRβ, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information,” *Cancer Biology & Therapy*, vol. 6, no. 7, pp. 1018–1024, 2007.

[141] R. Lima e Silva, J. Shen, S. F. Hackett, et al., “The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization,” *The FASEB Journal*, vol. 21, no. 12, pp. 3219–3230, 2007.

[142] C. K. Williams, M. Segarra, M. De La Luz Sierra, R. C. A. Sainson, G. Tosato, and A. L. Harris, "Regulation of CXCR4 by the notch ligand delta-like 4 in endothelial cells,” *Cancer Research*, vol. 68, no. 6, pp. 1889–1895, 2008.

[143] X. Hong, F. Jiang, S. N. Kalkanis, et al., "SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion,” *Cancer Letters*, vol. 236, no. 1, pp. 39–45, 2006.

[144] R. E. Bachelder, M. A. Wendt, and A. M. Mercurio, “Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4,” *Cancer Research*, vol. 62, no. 24, pp. 7203–7206, 2002.

[145] R. Salcedo, K. Wasserman, H. A. Young, et al., "Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells. In vivo neovascularization induced by stromal-derived factor-1α,” *The American Journal of Pathology*, vol. 154, no. 4, pp. 1125–1135, 1999.

[146] D. Zaggag, Y. Lukyanov, L. Lan, et al., "Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion,” *Laboratory Investigation*, vol. 86, no. 12, pp. 1221–1232, 2006.

[147] Z. Liang, J. Brooks, M. Willard, et al., “CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway,” *Biochemical and Biophysical Research Communications*, vol. 359, no. 3, pp. 716–722, 2007.

[148] D. D. Billadeau, S. Chatterjee, P. Bramati, et al., “Characterization of the CXCR4 signaling in pancreatic cancer cells,” *International Journal of Gastrointestinal Cancer*, vol. 37, no. 4, pp. 110–119, 2006.

[149] J. Wang, J. Wang, Y. Sun, et al., “Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis,” *Cellular Signalling*, vol. 17, no. 12, pp. 1578–1592, 2005.

[150] Y.-P. Jiang, X.-H. Wu, H.-Y. Xing, and X.-Y. Du, "Role of CXCL12 in metastasis of human ovarian cancer,” *Chinese Medical Journal*, vol. 120, no. 14, pp. 1251–1253, 2007.

[151] M. Darash-Yahana, E. Pikarsky, R. Abramovitch, et al., "Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis,” *The FASEB Journal*, vol. 18, no. 11, pp. 1240–1242, 2004.

[152] S.-X. Yang, J.-H. Chen, X.-F. Jiang, et al., "Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor,” *Biochemical and Biophysical Research Communications*, vol. 335, no. 2, pp. 523–528, 2005.

[153] J. Kijowski, M. Baj-Krzyworzeka, M. Majka, et al., “The SDF-1/CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells,” *Stem Cells*, vol. 19, no. 5, pp. 453–466, 2001.

[154] D. W. Miles, L. C. Happerfield, M. S. Naylor, L. G. Bobrow, R. D. Rubens, and F. R. Balkwill, “Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissue,” *International Journal of Cancer*, vol. 56, no. 6, pp. 777–782, 1994.

[155] J. W. Pollard, “Tumour-educated macrophages promote tumour progression and metastasis,” *Nature Reviews Cancer*, vol. 4, no. 1, pp. 71–78, 2004.

[156] F. Balkwill, “TNF-α in promotion and progression of cancer,” *Cancer and Metastasis Reviews*, vol. 25, no. 3, pp. 409–416, 2006.

[157] H. Kulbe, T. Hagemann, P. W. Szlosarek, F. R. Balkwill, and J. L. Wilson, “The inflammatory cytokine tumor necrosis factor-α regulates chemokine receptor expression on ovarian cancer cells,” *Cancer Research*, vol. 65, no. 22, pp. 10355–10362, 2005.

[158] J.-W. Oh, K. Drabik, O. Kutsch, C. Choi, A. Tousson, and E. N. Benveniste, “CXC chemokine receptor 4 expression and function in human astroglioma cells,” *The Journal of Immunology*, vol. 166, no. 4, pp. 2695–2704, 2001.

[159] H. K. Kleinman and G. R. Martin, “Matrigel: basement membrane matrix with biological activity,” *Seminars in Cancer Biology*, vol. 15, no. 5, pp. 378–386, 2005.

[160] C. E. Eberhart, R. J. Coffey, A. Radhika, F. M. Giardiello, S. Ferrenbach, and R. N. DuBois, “Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas,” *Gastroenterology*, vol. 107, no. 4, pp. 1183–1188, 1994.

[161] W. Kutchera, D. A. Jones, N. Matsunami, et al., “Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 10, pp. 4816–4820, 1996.

[162] J. Dimberg, A. Samuelsson, A. Hugander, and P. Söderkvist, “Differential expression of cyclooxygenase 2 in human colorectal cancer,” *Gut*, vol. 45, no. 5, pp. 730–732, 1999.

[163] L. T. Soumaoro, H. Uetake, T. Higuchi, Y. Takagi, M. Enomoto, and K. Sugihara, “Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer,” *Clinical Cancer Research*, vol. 10, no. 24, pp. 8465–8471, 2004.
[164] C. H. Liu, S.-H. Chang, K. Narko, et al., “Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice,” The Journal of Biological Chemistry, vol. 276, no. 21, pp. 18563–18569, 2001.

[165] S.-H. Chang, C. H. Liu, R. Conway, et al., “Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase-2 induced breast cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 2, pp. 591–596, 2004.

[166] S.-H. Chang, Y. Ai, R. M. Breyer, T. F. Lane, and T. Hla, “The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia,” Cancer Research, vol. 65, no. 11, pp. 4496–4499, 2005.

[167] R. A. Gupta and R. N. DuBois, “Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2,” Nature Reviews Cancer, vol. 1, no. 1, pp. 11–21, 2001.

[168] L. J. Marnett and R. N. Dubois, “COX-2: a target for colon cancer prevention,” Annual Review of Pharmacology and Toxicology, vol. 42, pp. 55–80, 2002.

[169] D. Wang, J. R. Mann, and R. N. DuBois, “The role of prostaglandins and other eicosanoids in the gastrointestinal tract,” Gastroenterology, vol. 128, no. 5, pp. 1445–1461, 2005.

[170] B. Rigas, I. S. Goldman, and L. Levine, “Altered eicosanoid levels in human colon cancer,” Journal of Laboratory and Clinical Medicine, vol. 122, no. 5, pp. 518–523, 1993.

[171] S. Pugh and G. A. Thomas, “Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2,” Gut, vol. 35, no. 5, pp. 675–678, 1994.

[172] R. N. Dubois, L. M. Hylland, C. R. Robinson, et al., “Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis,” Digestive Diseases and Sciences, vol. 43, no. 2, pp. 311–316, 1998.

[173] A. F. Badawi and M. Z. Badr, “Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ and levels of prostaglandin E2 and 15-deoxy-Δ12,14-prostaglandin J1 in human breast cancer and metastasis,” International Journal of Cancer, vol. 103, no. 1, pp. 84–90, 2003.

[174] M. G. Backlund, J. R. Mann, V. R. Holla, et al., “15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer,” The Journal of Biological Chemistry, vol. 280, no. 5, pp. 3217–3223, 2005.

[175] A. S. Soydan, I. A. Tavares, P. K. Weech, N. M. Tremblay, and A. Bennett, “High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue,” European Journal of Cancer, vol. 32, no. 10, pp. 1781–1787, 1996.

[176] J. Dimberg, A. Samuelsson, A. Hugander, and P. Söderkvist, “Gene expression of cyclooxygenase-2 group II and cytosolic phospholipase A2 in human colorectal cancer,” Anticancer Research, vol. 18, no. 5A, pp. 3283–3287, 1998.

[177] A. Österström, J. Dimberg, K. Fransen, and P. Söderkvist, “Expression of cytosolic and group X secretory phospholipase A2 genes in human colorectal adenocarcinomas,” Cancer Letters, vol. 182, no. 2, pp. 175–182, 2002.

[178] L. Qiao, V. Kozoni, G. J. Tsioulas, et al., “Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo,” Biochimica et Biophysica Acta, vol. 1238, no. 2, pp. 215–223, 1995.

[179] D. Wang, F. G. Buchanan, H. Wang, S. K. Dey, and R. N. DuBois, “Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade,” Cancer Research, vol. 65, no. 5, pp. 1822–1829, 2005.

[180] A. V. Timoshenko, G. Xu, S. Chakrabarti, P. K. Lala, and C. Chakraborty, “Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells,” Experimental Cell Research, vol. 289, no. 2, pp. 265–274, 2003.

[181] R. Pai, B. Soreghan, I. L. Szabo, M. Pavelka, D. Baatar, and A. S. Tarnawski, “Prostaglandin E2, transactivates EGFR receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy,” Nature Medicine, vol. 8, no. 3, pp. 289–293, 2002.

[182] C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001.

[183] L. Ermert, C. Dierkes, and M. Ermert, “Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors,” Clinical Cancer Research, vol. 9, no. 5, pp. 1604–1610, 2003.

[184] F. A. Fitzpatrick and M. A. Wynnala, “Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro,” The Journal of Biological Chemistry, vol. 258, no. 19, pp. 11713–11718, 1983.

[185] C. Aussel, D. Mary, and M. Fehlmann, “Prostaglandin synthesis in human T cells: its partial inhibition by lectins and anti-CD3 antibodies as a possible step in T cell activation,” The Journal of Immunology, vol. 138, no. 10, pp. 3094–3099, 1987.

[186] O. Ishihara, M. H. F. Sullivan, and M. G. Elder, “Differences of metabolism of prostaglandin E2 and P2Y by decidual stromal cells and macrophages in culture,” Eicosanoids, vol. 4, no. 4, pp. 203–207, 1991.

[187] A. M. Joubert, A. Panzer, P. C. Bianchi, and M.-L. Lottering, “The effects of prostaglandin A2 on cell growth, cell cycle status and apoptosis induction in HeLa and MCF-7 cells,” Cancer Letters, vol. 191, no. 2, pp. 203–209, 2003.

[188] T. Yoshida, S. Ohki, M. Kanazawa, et al., “Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer,” Surgery Today, vol. 26, no. 7, pp. 740–745, 1998.

[189] S. Narumiya and M. Fukushima, “Δ1–15-prostaglandin J2, an ultimate metabolite of prostaglandin D2 exerting cell growth inhibition,” Biochemical and Biophysical Research Communications, vol. 127, no. 3, pp. 739–745, 1985.

[190] C. E. Clay, A. M. Namen, G.-I. Atsumi, et al., “Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells,” Carcinogenesis, vol. 20, no. 10, pp. 1905–1911, 1999.

[191] S. Kitamura, Y. Miyazaki, Y. Shinomura, S. Kondo, S. Kanayama, and Y. Matsuizawa, “Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells,” Japanese Journal of Cancer Research, vol. 90, no. 1, pp. 75–80, 1999.

[192] T. Shimada, K. Kojima, K. Yoshiura, H. Hiraishi, and A. Terano, “Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells,” Gut, vol. 50, no. 5, pp. 658–664, 2002.

[193] E. Mueller, M. Smith, P. Sarraf, et al., “Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10990–10995, 2000.

[194] R. Piva, P. Gianferrtetti, A. Ciucci, R. Taulli, G. Belardo, and A. Terrano, “Characteristics of the peroxisome proliferator-activated receptor γ ligand induced apoptosis in colon cancer cells,” Gut, vol. 50, no. 5, pp. 658–664, 2002.

[195] T. Yoshida, S. Ohki, M. Kanazawa, et al., “Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer,” Surgery Today, vol. 26, no. 7, pp. 740–745, 1998.
antiapoptotic proteins,” *Blood*, vol. 105, no. 4, pp. 1750–1758, 2005.

[195] T. Shibata, M. Kondo, T. Osawa, N. Shibata, M. Kobayashi, and K. Uchida, “15-deoxy-Δ12,14-prostaglandin J2: A prostaglandin D2 metabolite generated during inflammatory processes,” *The Journal of Biological Chemistry*, vol. 277, no. 12, pp. 10459–10466, 2002.

[196] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” *Cell*, vol. 83, no. 5, pp. 803–812, 1995.

[197] S. A. Kliewer, J. M. Lenhard, T. M. Wilson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” *Cell*, vol. 83, no. 5, pp. 813–819, 1995.

[198] B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” *Pharmacological Research*, vol. 51, no. 2, pp. 85–94, 2000.

[199] R. N. DuBois, R. Gupta, J. Brockman, B. S. Reddy, S. L. Krakow, and M. A. Lazar, “The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers,” *Carcinogenesis*, vol. 19, no. 1, pp. 49–53, 1998.

[200] J. A. Brockman, R. A. Gupta, and R. N. DuBois, “Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells,” *Gastroenterology*, vol. 115, no. 5, pp. 1049–1055, 1998.

[201] E. Elstner, C. Müller, K. Koshizuka, et al., “Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 15, pp. 8806–8811, 1998.

[202] J. Kim, P. Yang, M. Suraokar, et al., “Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products,” *Cancer Research*, vol. 65, no. 14, pp. 6189–6198, 2005.

[203] R. Grau, M. A. Iniguez, and M. Fresno, “Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Δ12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-γ-independent mechanism,” *Cancer Research*, vol. 64, no. 15, pp. 5162–5171, 2004.

[204] C. L. Richard, E. L. Lownthers, and J. Blay, “15-deoxy-Δ12,14-prostaglandin J2 down-regulates CXCR4 on carcinoma cells through PPARγ and NFκB-mediated pathways,” *Experimental Cell Research*, vol. 313, no. 16, pp. 3446–3458, 2007.

[205] C. Qin, R. Burghardt, R. Smith, M. Wormke, J. Stewart, and S. Safe, “Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells,” *Cancer Research*, vol. 63, no. 5, pp. 958–964, 2003.

[206] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkinson, T. M. Wilson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” *The Journal of Biological Chemistry*, vol. 270, no. 22, pp. 12953–12956, 1995.

[207] G. Lee, F. Elwood, J. McNally, et al., “T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities,” *The Journal of Biological Chemistry*, vol. 277, no. 22, pp. 19649–19657, 2002.

[208] L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe, et al., “Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662,” *Biochemistry*, vol. 41, no. 21, pp. 6640–6650, 2002.

[209] T. M. Lindström and P. R. Bennett, “15-deoxy-Δ12,14-prostaglandin J2 inhibits interleukin-1β-induced nuclear factor-κB in human amnion and myometrial cells: mechanisms and implications,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 90, no. 6, pp. 3534–3543, 2005.

[210] T. Shiraki, N. Kamiya, S. Shiki, T. S. Kodama, A. Kakizuka, and H. Jingami, “α,β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ,” *The Journal of Biological Chemistry*, vol. 280, no. 14, pp. 14145–14153, 2005.

[211] D. S. Straus, G. Pascual, M. Li, et al., “15-deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 9, pp. 4844–4849, 2000.

[212] A. Rossi, P. Kapahi, G. Natoli, et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of iκB kinase,” *Nature*, vol. 403, no. 6765, pp. 103–118, 2000.

[213] R. Schuligoi, M. Grill, A. Heinemann, B. A. Peskar, and R. Amann, “Sequential induction of prostaglandin E and D synthases in inflammation,” *Biochemical and Biophysical Research Communications*, vol. 335, no. 3, pp. 684–689, 2005.

[214] L. Saso, M. G. Leone, C. Sorrentino, et al., “Quantification of prostaglandin D synthetase in cerebrospinal fluid: a potential marker for brain tumor,” *Biochemistry & Molecular Biology International*, vol. 46, no. 4, pp. 643–656, 1998.

[215] C. M. Paumi, M. Wright, A. J. Townsend, and C. S. Morrow, “Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Δ12,14-prostaglandin J2 in MCF7 breast cancer cells,” *Biochemistry*, vol. 42, no. 18, pp. 5429–5437, 2003.

[216] C. M. Paumi, P. K. Smitherman, A. J. Townsend, and C. S. Morrow, “Glutathione S-transferases (GSTs) inhibit transcriptional activation by the peroxisomal proliferator-activated receptor γ (PPARγ) ligand, 15-deoxy-Δ12,14-prostaglandin J2 (15-d-PGJ2),” *Biochemistry*, vol. 43, no. 8, pp. 2345–2352, 2004.

[217] M. J. Reginato, S. T. Bailey, S. L. Krakow, et al., “A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties,” *The Journal of Biological Chemistry*, vol. 273, no. 49, pp. 32679–32684, 1998.

[218] H. S. Camp, O. Li, S. C. Wise, et al., “Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone,” *Diabetes*, vol. 49, no. 4, pp. 539–547, 2000.